WHO drug information. Vol. 28 No. 2 2014. / by World Health Organization.

Format:

Book

Author/Creator:

World Health Organization, author.

Language:

English

Subjects (All):

Drugs--Standards--Periodicals.

Drugs.

Drugs--Standards.

Physical Description:

1 online resource (171 p.)

Place of Publication:

London, England : World Health Organization, [2014]

Summary:

WHO Drug Information communicates pharmaceutical information that is either developed and issued by WHO or transmitted to WHO by research and regulatory agencies throughout the World. The journal also includes regular presentations of newly proposed and recommended International Nonproprietary Names (INN) for Pharmaceuticals Substances. This volume contains the proposed INN List No.111.

Contents:

""Cover""; ""Cover""; ""Contents""; ""Contents""; ""Regulatory harmonization""; ""Regulatory harmonization""; ""WHO collaboration with world pharmacopoeias""; ""WHO collaboration with world pharmacopoeias""; ""Technologies, standards and norms""; ""Technologies, standards and norms""; ""Quality standards for pharmaceutical products""; ""Quality standards for pharmaceutical products""; ""Essential medicines""; ""Essential medicines""; ""Intensified efforts required to withdraw oral artemisinin-based monotherapies""

""Intensified efforts required to withdraw oral artemisinin-based monotherapies""""Safety and efficacy news""; ""Safety and efficacy news""; ""Substandard and falsified products""; ""Substandard and falsified products""; ""Falsified antimalarial medicines in West and Central Africa""; ""Falsified antimalarial medicines in West and Central Africa""; ""Stolen trastuzumab, pemetrexed and infliximab in Europe""; ""Stolen trastuzumab, pemetrexed and infliximab in Europe""; ""Safety Information""; ""Safety Information""; ""Diacerein-containing medicines: restricted use""

""Diacerein-containing medicines: restricted use""""Domperidone: adverse effects on the heart""; ""Domperidone: adverse effects on the heart""; ""Hydroxyethyl starch-containing products: increased risk for patients with sepsis""; ""Hydroxyethyl starch-containing products: increased risk for patients with sepsis""; ""Epidural corticosteroid injection: rare but serious neurologic problems""; ""Epidural corticosteroid injection: rare but serious neurologic problems""; ""Zolpidem, eszopiclone: impaired next-day alertness""; ""Zolpidem, eszopiclone: impaired next-day alertness""

""Mirtazapine: abnormal heart rhythm""""Mirtazapine: abnormal heart rhythm""; ""Vemurafenib: liver problems""; ""Vemurafenib: liver problems""; ""Filgrastim and pegfilgrastim: capillary leak syndrome""; ""Filgrastim and pegfilgrastim: capillary leak syndrome""; ""Belimumab: opportunistic brain infection""; ""Belimumab: opportunistic brain infection""; ""Temozolomide: liver injury""; ""Temozolomide: liver injury""; ""RAS-acting agents: not to be used in combination""; ""RAS-acting agents: not to be used in combination""; ""TNF-alpha inhibitors: reactivation of tuberculosis""

""TNF-alpha inhibitors: reactivation of tuberculosis""""Arsenic-containing dental pastes: genotoxicity""; ""Arsenic-containing dental pastes: genotoxicity""; ""Serotonin-blocking medicines: serotonin syndrome""; ""Serotonin-blocking medicines: serotonin syndrome""; ""Panitumumab: rare but severe skin reactions""; ""Panitumumab: rare but severe skin reactions""; ""Reviews started""; ""Reviews started""; ""Overview of safety reviews started""; ""Overview of safety reviews started""; ""Regulatory news""; ""Regulatory news""; ""Pre-marketing assessment""; ""Pre-marketing assessment""

""EMA launches adaptive licensing pilot project""

Notes:

Description based upon print version of record.

Description based on print version record.

ISBN:

92-4-069332-7

OCLC:

891449722